Polyneuron is a pharmaceutical company that develops drugs for the treatment of antibody-mediated autoimmune diseases of the nervous system. Their biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patients with immune disorders in a safe and effective manner. The company markets its products in Switzerland.


Estimated Revenue: CHF 36.5
Headquarters: Basel, Switzerland
Industry: Biotechnology